1553 related articles for article (PubMed ID: 26451651)
1. Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Riaz S; Khan IU; Bajda M; Ashraf M; Qurat-Ul-Ain ; Shaukat A; Rehman TU; Mutahir S; Hussain S; Mustafa G; Yar M
Bioorg Chem; 2015 Dec; 63():64-71. PubMed ID: 26451651
[TBL] [Abstract][Full Text] [Related]
2. 2-Furoic piperazide derivatives as promising drug candidates of type 2 diabetes and Alzheimer's diseases: In vitro and in silico studies.
Abbasi MA; Hassan M; Ur-Rehman A; Siddiqui SZ; Hussain G; Shah SAA; Ashraf M; Shahid M; Seo SY
Comput Biol Chem; 2018 Dec; 77():72-86. PubMed ID: 30245349
[TBL] [Abstract][Full Text] [Related]
3. Novel pyridine-2,4,6-tricarbohydrazide thiourea compounds as small key organic molecules for the potential treatment of type-2 diabetes mellitus: In vitro studies against yeast α- and β-glucosidase and in silico molecular modeling.
Rehman TU; Riaz S; Khan IU; Ashraf M; Bajda M; Gawalska A; Yar M
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29194730
[TBL] [Abstract][Full Text] [Related]
4. Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies.
Mutahir S; Jończyk J; Bajda M; Khan IU; Khan MA; Ullah N; Ashraf M; Qurat-ul-Ain ; Riaz S; Hussain S; Yar M
Bioorg Chem; 2016 Feb; 64():13-20. PubMed ID: 26595185
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of some new N-(alkyl/aralkyl)-N-(2,3-dihydro-1,4-benzodioxan-6-yl)-4-chlorobenzenesulfonamides as possible therapeutic agents for Alzheimer's disease and Type-2 Diabetes.
Abbasi MA; Rehman A; Siddiqui SZ; Hadi N; Mumtaz A; Shah SAA; Ashraf M; Abbasi GH
Pak J Pharm Sci; 2019 Jan; 32(1):61-68. PubMed ID: 30772791
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Characterization, and Inhibition Study of Novel Substituted Phenylureido Sulfaguanidine Derivatives as α-Glycosidase and Cholinesterase Inhibitors.
Akocak S; Taslimi P; Lolak N; Işık M; Durgun M; Budak Y; Türkeş C; Gülçin İ; Beydemir Ş
Chem Biodivers; 2021 Apr; 18(4):e2000958. PubMed ID: 33620128
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Anticholinergic and Antidiabetic Properties of Some Natural and Synthetic Molecules: An
Çomaklı V; Aygül İ; Sağlamtaş R; Kuzu M; Demirdağ R; Akincioğlu H; Adem Ş; Gülçin İ
Curr Comput Aided Drug Des; 2024; 20(5):441-451. PubMed ID: 37202895
[TBL] [Abstract][Full Text] [Related]
8. Comparative Cholinesterase, α-Glucosidase Inhibitory, Antioxidant, Molecular Docking, and Kinetic Studies on Potent Succinimide Derivatives.
Ahmad A; Ullah F; Sadiq A; Ayaz M; Saeed Jan M; Shahid M; Wadood A; Mahmood F; Rashid U; Ullah R; Sahibzada MUK; Alqahtani AS; Mahmood HM
Drug Des Devel Ther; 2020; 14():2165-2178. PubMed ID: 32606589
[TBL] [Abstract][Full Text] [Related]
9. An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.
Rehman TU; Khan IU; Ashraf M; Tarazi H; Riaz S; Yar M
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220522
[TBL] [Abstract][Full Text] [Related]
10. Novel pyridine-2,4,6-tricarbohydrazide derivatives: design, synthesis, characterization and in vitro biological evaluation as α- and β-glucosidase inhibitors.
Riaz S; Khan IU; Yar M; Ashraf M; Rehman TU; Shaukat A; Jamal SB; Duarte VCM; Alves MJ
Bioorg Chem; 2014 Dec; 57():148-154. PubMed ID: 25462991
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking, and biological activities of new cyanopyridine derivatives containing phenylurea.
Gezegen H; Gürdere MB; Dinçer A; Özbek O; Koçyiğit ÜM; Taslimi P; Tüzün B; Budak Y; Ceylan M
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000334. PubMed ID: 33300644
[TBL] [Abstract][Full Text] [Related]
12. New 6-amino-pyrido[2,3-d]pyrimidine-2,4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, α-glucosidase inhibition, molecular modeling and kinetic study.
Adib M; Peytam F; Rahmanian-Jazi M; Mahernia S; Bijanzadeh HR; Jahani M; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Mahdavi M; Larijani B
Eur J Med Chem; 2018 Jul; 155():353-363. PubMed ID: 29902721
[TBL] [Abstract][Full Text] [Related]
13. Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α-glucosidase, α-amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation.
Ragab A; Salem MA; Ammar YA; Aboulthana WM; Helal MH; Abusaif MS
Drug Dev Res; 2024 Jun; 85(4):e22216. PubMed ID: 38831547
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of the α-glucosidase and butyrylcholinesterase studied by molecular field topology analysis.
Jabeen F; Oliferenko PV; Oliferenko AA; Pillai GG; Ansari FL; Hall CD; Katritzky AR
Eur J Med Chem; 2014 Jun; 80():228-42. PubMed ID: 24780600
[TBL] [Abstract][Full Text] [Related]
15. A new entry into the portfolio of α-glucosidase inhibitors as potent therapeutics for type 2 diabetes: Design, bioevaluation and one-pot multi-component synthesis of diamine-bridged coumarinyl oxadiazole conjugates.
Kazmi M; Zaib S; Ibrar A; Amjad ST; Shafique Z; Mehsud S; Saeed A; Iqbal J; Khan I
Bioorg Chem; 2018 Apr; 77():190-202. PubMed ID: 29421697
[TBL] [Abstract][Full Text] [Related]
16. Exploration of aroyl/heteroaroyl iminothiazolines featuring 2,4,5-trichlorophenyl moiety as a new class of potent, selective, and in vitro efficacious glucosidase inhibitors.
Kazmi M; Zaib S; Amjad ST; Khan I; Ibrar A; Saeed A; Iqbal J
Bioorg Chem; 2017 Oct; 74():134-144. PubMed ID: 28780150
[TBL] [Abstract][Full Text] [Related]
17. Multitargeted inhibition of key enzymes associated with diabetes and Alzheimer's disease by 1,3,4-oxadiazole derivatives: Synthesis, in vitro screening, and computational studies.
Fatima B; Saleem F; Salar U; Chigurupati S; Felemban SG; Ul-Haq Z; Tariq SS; Almahmoud SA; Taha M; Shah STA; Khan KM
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300384. PubMed ID: 37806747
[TBL] [Abstract][Full Text] [Related]
18. Novel synthesis of dihydropyrimidines for α-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.
Yar M; Bajda M; Shahzadi L; Shahzad SA; Ahmed M; Ashraf M; Alam U; Khan IU; Khan AF
Bioorg Chem; 2014 Jun; 54():96-104. PubMed ID: 24880489
[TBL] [Abstract][Full Text] [Related]
19. Potential antioxidant, α-glucosidase, butyrylcholinesterase and acetylcholinesterase inhibitory activities of major constituents isolated from
Al Garni HA; El-Halawany AM; Koshak AE; Malebari AM; Alzain AA; Mohamed GA; Ibrahim SRM; El-Sayed NS; Abdallah HM
SAR QSAR Environ Res; 2024 May; 35(5):391-410. PubMed ID: 38769919
[No Abstract] [Full Text] [Related]
20. Hydrazinyl arylthiazole based pyridine scaffolds: Synthesis, structural characterization, in vitro α-glucosidase inhibitory activity, and in silico studies.
Ali F; Khan KM; Salar U; Taha M; Ismail NH; Wadood A; Riaz M; Perveen S
Eur J Med Chem; 2017 Sep; 138():255-272. PubMed ID: 28672278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
